Cardiology Archives

Draeger Infinity Acute Care System Coming to North America

by Gene Ostrovsky on May 23, 2012 •

Infinity Acute Care System Draeger Infinity Acute Care System Coming to North America
Dräger is bringing its Infinity Acute Care System, an advanced ICU monitoring package, to the U.S. and Canada. The system features a wireless patient monitor that stays attached to the bed, allowing for quick movement of patients between different clinical departments without ever losing live data feeding back to the central console.

The Infinity includes Masimo’s complete rainbow SET noninvasive Pulse CO-Oximetry, interfaces with Dräger’s ventilators, and the “Medical Cockpit” integrates the data with information from the EMR including diagnostic images and patient history.

Details of the Infinity Acute Care System from the product page:

Infinity M540 Patient MonitorDraeger Infinity M5401 Draeger Infinity Acute Care System Coming to North America
Handheld
Lightweight, durable and reliable (1.2 kg / 2.6 lbs, including battery)

System connectivity
Provides system networking and communication between the M540 and Medical Cockpit via the P2500 Power Supply

Water-resistant
Splash-resistant and submersible for protection against fluids

Wireless transport
Undocks at the bedside with the press of a but ton for transport, then automatically sends data wirelessly to the Infinity Network

Portable
Accompanies the patient throughout the hospital and in a land ambulance

Infinity M500 Docking Station
System connectivity
Provides system networking and communication between the M540 and Medical Cockpit via the P2500 Power Supply

Rechargeable
Powers the M540 when docked, recharging the internal battery for transport

Draeger Infinity M540 full1 Draeger Infinity Acute Care System Coming to North AmericaInfinity Medical Cockpit

360° alarm light
Enables caregivers to see alarms from anywhere in the room

Integrated information
Provides easy access to vital signs data, clinical applications, the hospital network, and the intranet at the point of care

Widescreen display
Large 20” (C700) or 17” (C500) touch-screen display makes information easy to see from any angle

Infection-resistant
Fanless, easy-to-clean design reduces risk of cross-contamination

Product page: Infinity Acute Care System…

Press release: Dräger launches breakthrough Infinity® Acute Care System monitoring solution in North America…

Cardiac Surgery / Cardiology / Radiology / Vascular Surgery

OrbusNeich’s Combo Dual Therapy Stent Continues to Show Promise in Clinical Trial

by Brian Klein on May 22, 2012
OrbusNeich's Combo Dual Therapy Stent Continues to Show Promise in Clinical Trial

In November 2011, we reported the preliminary results of the REMEDEE clinical trial for the Combo Dual Therapy stent from OrbusNeich (Hoevelaken, Netherlands). The stent was developed to promote endovascular healing and cut the risk of restenosis compared to current bare-metal and drug-eluting stents. The randomized REMEDEE trial (Randomized Evaluation of an abluMinal sirolimus coatED bio- Engineered stEnt) found that the Combo Dual Therapy stent was non-inferior to the TAXUS Liberté paclitaxel-eluting stent based on in-stent late lumen loss at nine months.

More recently, at EuroPCR 2012, the company has announced the 12-month follow-up from the study. Data from that study indicate that the stent was associated with favorable clinical and safety outcomes over the TAXUS Liberté stent.

Read More

Cardiology / Radiology

Medtronic’s Resolute Integrity DES Grabs New Indications in EU

by Gene Ostrovsky on May 21, 2012
Medtronic's Resolute Integrity DES Grabs New Indications in EU

Medtronic has received expanded clearance for a bunch of new indications for its flagship Resolute Integrity drug eluting coronary stent in countries using the CE Mark. It was previously labeled for use in patients with diabetes and multi-vessel disease, but is now also approved for acute coronary syndromes, acute myocardial infarction, unstable angina, bifurcations, in-stent restenosis, total occlusions and chronic total occlusions.

Recent clinical study results, according to the latest company’s announcement:

Read More

Cardiac Surgery / Cardiology / Critical Care / Medgadget Exclusive / Surgery / Vascular Surgery

Five Questions for Dr. Paul Walker of Spectral Diagnostics

by Jan Sinnige on May 17, 2012
Five Questions for Dr. Paul Walker of Spectral Diagnostics

Sepsis is a huge problem, costing billions of dollars and hundreds of thousands of lives a year in the US alone. A Toronto, Canada-based startup Spectral Diagnostics Inc. is developing a promising technology to decrease morbidity and mortality of patients with sepsis. The company’s proprietary technology is integrated into Toraymyxin, a hemoperfusion adsorption column which is highly effective in removing circulating endotoxin from the bloodstream. Furthermore, Spectral Diagnostics has also developed the Endotoxin Activity Assay (EAA) – the only FDA cleared, CE marked rapid diagnostic for endotoxemia. According to a company representative, in 2009 interim results of a Phase II study were published in JAMA demonstrating that “Toraymyxin, when added to conventional therapy, significantly reduced 28-day mortality in patients with severe sepsis and septic shock, compared to patients only receiving conventional therapy. Due to these positive results, that trial was terminated early and a Phase III pivotal multicenter study has been launched in the U.S. and Canada.” To find out more about this technology and its future, we had a chance to conduct an interview with Dr. Paul Walker, President and CEO of Spectral Diagnostics.

Dr. Jan Sinnige, Medgadget: Spectral Diagnostics recently started a phase three randomized controlled trial on Polymyxin B Hemoperfusion. What are the expectations according to the phase two results?

Read More

Cardiac Surgery / Cardiology / Radiology

BIOTRONIK’s Lumax 740 ICD Debuts in the U.S.

by Brian Klein on May 14, 2012
BIOTRONIK’s Lumax 740 ICD Debuts in the U.S.

The FDA has approved the Lumax 740 implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy devices (CRT-D) from BIOTRONIK.

The Lumax 740 line, which was designed to help physicians monitor and treat arrhythmias and heart failure, features the company’s proprietary SMART Detection technology to reduce the incidence of inappropriate shocks to the heart.

Read More

Anesthesiology / Cardiology / Critical Care / Emergency Medicine / Medicine / Military Medicine / Ob/Gyn

GE Upgrades Its Portable Vscan Ultrasound

by Gene Ostrovsky on May 11, 2012
GE Upgrades Its Portable Vscan Ultrasound

GE Healthcare has unveiled the new and improved version of its popular Vscan pocket-sized ultrasound. The Vscan 1.2 sports a longer lasting battery, a new interface, and improved data export capabilities to help with reporting and sharing info about patients.

Full list of new features in the Vscan 1.2 according to the GE announcement:

Read More

Anesthesiology / Cardiac Surgery / Cardiology / Critical Care

BIOTRONIK’s Reocor External Pacemaker Now Available in U.S.

by Gene Ostrovsky on May 11, 2012
BIOTRONIK's Reocor External Pacemaker Now Available in U.S.

BIOTRONIK is bringing to the U.S. the Reocor external pacemarker, that is available in two models for dual- and single-chamber pacing.

The company is touting the system’s design and intuitive controls, as well as a longer lasting battery that will work for 600 hours of permanent pacing on the Reocor S model.

Read More

Cardiac Surgery / Cardiology

Boston Scientific’s Latest Bradycardia Pacemakers Get FDA OK

by Gene Ostrovsky on May 8, 2012
Boston Scientific's Latest Bradycardia Pacemakers Get FDA OK

Boston Scientific received FDA approval and is releasing in the U.S. the INGENIO and ADVANTIO pacemakers and INVIVE cardiac resynchronization therapy pacemakers (CRT-P).

The devices are indicated for treatment of bradycardia, and the INGENIO and ADVANTIO pacemakers specifically feature BostonSci’s RightRate technology for addressing chronotropic incompetence, a condition in which the heart is unable to regulate its rate appropriately in response to physiologic stress, such as an exercise.

Read More

Cardiology / Medicine / Radiology / Vascular Surgery

Vessix V2 Renal Denervation System Receives CE Mark Approval

by Wouter Stomp on May 2, 2012
Vessix V2 Renal Denervation System Receives CE Mark Approval

Just two days after we reported on the design story behind the Vessix V2 renal denervation system,Vessix Vascular is now announcing it has received European CE Mark approval for its percutaneous radiofrequency balloon catheter technology for the treatment of hypertension. According to the company, the system is faster, easier to use and less painful for patients than any renal denervation system currently available on the market.

The V2 is approved for use in patients with uncontrolled hypertension despite taking three or more anti-hypertensive medications. In these patients, renal denervation may reduce systolic blood pressure by approximately 20 percent, thereby greatly reducing the risk of stroke and cardiovascular disease.

Read More

12345678910

Follow Medgadget on Twitter